1. Parker HE，Habib AM，Rogers GJ. et al. Nutrient-dependent secretion of glucose—dependent insulinotropic polypeptide from primary murine K cells.Diabetologia 2009，52：289-298.

2. Reimann F. Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int Dairy J 2010，20：236-242.

3. Ellrichmann M，Kapelle M，Ritter PR，et al. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1 （7-36） -amide-1，cholecystokinin，and peptide YY concentrations.J Clin Endocrinol Metab 2008，93：3995-3998.

4. Mayo KE，Miller LJ，Bataille D，et al. International Union of Pharmacology.XXXV.The glucagon receptor family. Pharmacol Rev 2003，55（1）：167-194.

5. Reimann F. Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int Dairy J 2010，20：236-242.

6. Ellrichmann M，Kapelle M，Ritter PR，et al. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1 （7-36） -amide-1，cholecystokinin，and peptide YY concentrations.J Clin Endocrinol Metab 2008，93：3995-3998.

7. Holz G G，Leech C A，Heller R S，et al. cAMP-dependent mobilization of intracellular Ca ²⁺ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca ²⁺ signaling system stimulated by the insulinotropic hormone glucagon- like peptide-1-（7-37）. J Biol Chem，1999，274（20）：14147-14156.

8. Bode H P，Moormann B，Dabew R，et al. Glucagon-like peptide1 elevates cytosolic calcium in pancreatic b-cells independently of protein kinase A. Endocrinology，1999，140（9）：3919～3927.

9. GU W. NIE A H. LI S. Research development on DPP. Ⅳ's targeting T2DM drugs. Chin J Med Chem（中国药物化学杂志），2004，14（6）：373-378.

10. WEBER A E. Dipeptidyl peptidase Ⅳ inhibitors for the treatment of diabetes. J Med Chem，2004，47（17）：41354-41141.

11. Raufman J P，Singh L，Singh G，et al.Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.J Biol Chem，l992，267（30）：21432-21437.

12. Xiao Q，Giguere J，Parisien M，et al.Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.Biochemistry，2001，40（9）：2860-2869.

13. Neumiller JJ，Wood L，Campbell RK.et al.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy，2010，30（5）：463-484.

14. 苗新宇，刘瑜，李春霖.胰高血糖素样肽-1保护胰岛β细胞相关分子机制的研究进展.生物化学与生物物理进展，2013，40（6）：501-509.

15. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA，1992，89（18）：8641-8645.

16. Tibaduiza E C，Chen C，Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem，2001，276 （41）：37787-37793.

17. Gao H，Wang X，Zhang Z，et al. GLP-1 amplifies insulin signaling by up-regulation of IRβ，IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocr，2007，32：90-95.

18. Sancho V，Trigo ML，Martin-Duce A，et al. Effect of GLP-1 on D-glucose transport，lipolysis and lipogenesis，in adipocytes of obese subjects. Int J Mol Med，2006，17：1133-1137.

19. Sancho V，Nuche B，Arnes L，et al. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes，and on kinase activity as compared to morBidly obese patients. Int J Mol Med 2007，19：961-966.

20. Chai W，Dong Z，Wang N，et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes，2012，61 （4）：888-896.

21. Websky K，Reichetzeder C，Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens，2014，23（1）：54-60.

22. List JF，He H，Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regulatory Peptides 2006，134：149-157.

23. Zhou J，Wu J，Zheng F，et al. Glucagon-like peptide-1 analogue-mediated protection against cholesterol-induced apoptosis via mTOR activation in pancreatic βTC-6 cells. J Diabees 2014 Jun 9. doi：10.1111/1753-0407.12177.